Blend identity and evidence limits
Retatrutide + Cagrilintide Blend
A component-by-component evidence check that separates this proposed mixture from CagriSema.
Source and review status
Identity unresolved
Identity search checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
Two distinct research molecules
Retatrutide activates GIP, GLP-1 and glucagon receptors. Cagrilintide is a long-acting amylin analogue. The name of this proposed blend gives no verified information about its formulation or component ratio.
Sources: Jastreboff and colleagues, New England Journal of Medicine; indexed by Europe PMC, Lau and colleagues, The Lancet; indexed by PubMed
Why separate trials do not establish a blend
The cited retatrutide and cagrilintide trials assessed separate treatments. REDEFINE 1 assessed cagrilintide with semaglutide, a different partner. None of these studies tested this retatrutide mixture, so their weight results and adverse-event rates cannot be added together to predict its effects.
Sources: Jastreboff and colleagues, New England Journal of Medicine; indexed by Europe PMC, Lau and colleagues, The Lancet; indexed by PubMed, Garvey and colleagues, New England Journal of Medicine; indexed by Europe PMC
Status and remaining questions
FDA identifies neither retatrutide nor cagrilintide as a component of an FDA-approved drug. Their independent research histories do not establish a safe combination.
Sources: U.S. Food and Drug Administration
The blend remains unverified for composition, stability, interactions and clinical outcomes. A targeted search did not identify a primary human trial of this exact pairing; that finding is limited to the sources located at the check date.
Published sources
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
Jastreboff and colleagues, New England Journal of Medicine; indexed by Europe PMC. Published 26 June 2023 online; accessed 6 September 2026.
Supports: Triple-receptor identity, 338-participant trial, weight outcomes, gastrointestinal effects and heart-rate changes.
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau and colleagues, The Lancet; indexed by PubMed. Published 16 November 2021 online; accessed 6 September 2026.
Supports: Amylin-analogue identity and a 706-participant trial, including gastrointestinal adverse events. Not evidence for a retatrutide mixture.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey and colleagues, New England Journal of Medicine; indexed by Europe PMC. Published 22 June 2025 online; accessed 6 September 2026.
Supports: REDEFINE 1: 3,417 participants, 68-week weight outcomes and adverse events for the studied combination.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
U.S. Food and Drug Administration. Current FDA reference; accessed 6 September 2026.
Supports: U.S. status of retatrutide and cagrilintide and concerns about unapproved products sold for human use.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Identity and evidence limits documented | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.